title: [Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis].
abstract: OBJECTIVE
  To evaluate the clinical therapeutic value of (188)Re-HEDP combined with pamidronate in breast cancer with bone metastasis.
  
  
  METHODS
  Forty-eight patients with breast cancer with multi-bone metastases were randomly divided into three groups:15 patients received (188)Re-HEDP (group A), 15 patients received pamidronate (group B) and 18 patients were treated by (188)Re-HEDP plus pamidronate (group C).
  
  
  RESULTS
  The overall pain relief rate was 73.3%, 80.0%, 100.0% in groups A, B and C. The response rate of bone metastasis was 40.0%, 33.3%, 66.7% in groups A, B and C respectively. The therapeutic effect of group C was better than those of groups A and B (P < 0.05), without any significance in the difference (P > 0.05).
  
  
  CONCLUSIONS
  The therapeutic effect of (188)Re-HEDP combined with pamidronate for breast cancer with bone metastasis is remarkable in bone pain relief and bone metastasis control, which is better than either (188)Re-HEDP or pamidronate alone.
authors.affiliation: Department of Nuclear Medicine, Second Hospital, Sun Yat-sen University, Guangzhou 510120, China. liangjiugen@sohu.com
authors.forename: Jiu-gen
authors.initials: JG
authors.lastname: Liang
authors.forename: Ning-yi
authors.initials: NY
authors.lastname: Jiang
authors.forename: Jian-qiang
authors.initials: JQ
authors.lastname: DU
authors.forename: Xian-ping
authors.initials: XP
authors.lastname: Lu
authors.forename: Xing-guang
authors.initials: XG
authors.lastname: Liu
authors.forename: Shao-xiong
authors.initials: SX
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications / Q000556:secondary* / Q000628:therapy; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D002272:Carcinoembryonic Antigen / Q000097:blood; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010146:Pain / Q000209:etiology; D059408:Pain Management; D000077268:Pamidronate; D011868:Radioisotopes / Q000627:therapeutic use; D012211:Rhenium / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D002272:Carcinoembryonic Antigen; D004164:Diphosphonates; D009942:Organometallic Compounds; D011868:Radioisotopes; C101598:rhenium-186 HEDP; D012211:Rhenium; D012968:Etidronic Acid; D000077268:Pamidronate